ArticleOncoTargets and therapy2018

Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer.

Xiaoping Ouyang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.